Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 182, Issue 1, Pages 51-56Publisher
WILEY
DOI: 10.1111/cei.12665
Keywords
antibodies; B cell; immunodeficiency diseases
Categories
Funding
- CSL Behring
Ask authors/readers for more resources
Intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) are effective in the treatment of patients with primary antibody deficiency disorders (PAD). The purpose of this study was to evaluate Streptococcus pneumoniae (Spn) antibody titres to 14 serotypes in patients receiving IVIG compared to SCIG and to correlate Spn antibody levels to clinical outcome. The doses of immunoglobulin (Ig)G/kg/month were similar in both IVIG and SCIG groups. In 11 patients treated with IVIG, Spn antibody titres were13 g/ml to 994 +/- 21% of the 14 serotypes at peak IVIG but decreased to 669 +/- 198% at trough IVIG. Loss of Spn titres13 g/ml was most frequent for Spn serotypes 1, 4, 9V and 23. This correlated with lower Spn antibody titres to these serotypes at peak IVIG compared to the other serotypes. In 13 patients treated with SCIG, Spn antibody titres were protective to 582 +/- 233% of the serotypes 3-5 days after infusion, similar to trough IVIG. Similarly, the Spn serotypes with the least protective percentages were the same as the ones observed in trough IVIG. There were no annualized serious bacterial infections (aSBI) in either group. However, there were significantly decreased annualized other infections (aOI) in the SCIG group compared to the IVIG-treated group, 08 +/- 07 versus 22 +/- 12 infections/patient/year (P=0004). Breakthrough aOI did not correlate with protective or higher serum Spn antibody titres.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available